Mabion S.A. Stock price

Equities

MAB

PLMBION00016

Biotechnology & Medical Research

Delayed Warsaw S.E. 06:07:50 2024-03-28 am EDT 5-day change 1st Jan Change
16.3 PLN 0.00% Intraday chart for Mabion S.A. +0.37% -10.19%
Sales 2023 * 165M 41.18M Sales 2024 * 168M 41.84M Capitalization 263M 65.75M
Net income 2023 * 40M 9.98M Net income 2024 * 11M 2.75M EV / Sales 2023 * 1.49 x
Net cash position 2023 * 17.3M 4.32M Net Debt 2024 * 14.95M 3.73M EV / Sales 2024 * 1.66 x
P/E ratio 2023 *
7.87 x
P/E ratio 2024 *
15 x
Employees 252
Yield 2023 *
-
Yield 2024 *
-
Free-Float 63.7%
More Fundamentals * Assessed data
Dynamic Chart
1 week+0.37%
Current month-4.06%
1 month-5.23%
3 months-9.70%
6 months-1.93%
Current year-10.19%
More quotes
1 week
16.00
Extreme 16
16.45
1 month
16.00
Extreme 16
17.39
Current year
16.00
Extreme 16
21.18
1 year
15.80
Extreme 15.8
23.60
3 years
15.80
Extreme 15.8
110.00
5 years
15.80
Extreme 15.8
126.20
10 years
15.80
Extreme 15.8
139.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO 50 18-12-31
Chief Operating Officer - 09-10-28
Members of the board TitleAgeSince
Chief Executive Officer - -
Chairman 58 17-06-13
Director/Board Member 51 -
More insiders
Date Price Change Volume
24-03-28 16.3 0.00% 2 318
24-03-27 16.3 -0.49% 19,743
24-03-26 16.38 +0.99% 9,103
24-03-25 16.22 +1.00% 21,422
24-03-22 16.06 -1.11% 22,080

Delayed Quote Warsaw S.E., March 28, 2024 at 06:07 am EDT

More quotes
Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
3
Last Close Price
16.3 PLN
Average target price
15.57 PLN
Spread / Average Target
-4.50%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Mabion S.A. - Warsaw S.E.